AGI-41998
Based on 1 publication(s) in Google Scholar
AGI-41998 is a potent and orally active inhibitor of methionine adenosyltransferase 2A (MAT2A) that effectively penetrates the blood-brain barrier. AGI-41998 exhibits inhibitory activities against MAT2A and S-adenosyl methionine (SAM) in HCT-116 MTAP-null cells with IC50s of 22 nM and 34 nM. AGI-41998 can significantly inhibit the proliferation of HCT-116 cells and tumor growth. AGI-41998 can be used to study the role of SAM regulation in the central nervous system (CNS) and colon cancer.
For research use only. We do not sell to patients.
- Purity : 98.72%
- CAS No.: 2377492-26-5
- Formula: C22H16BrF3N4O2
- Molecular Weight:505.29
-
Storage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-145777
AGI-43192MAT2A Inhibitor -
HY-108501
(1R,1'S,3'R/1R,1'R,3'S)-L-054,264sst2 Agonist -
HY-P1932
Cortistatin-14Somatostatin Receptor Inhibitor -
HY-16381
PasireotideSomatostatin Agonist -
HY-16381A
Pasireotide acetateSomatostatin Agonist -
HY-79136
Pasireotide L-aspartate saltSomatostatin Agonist -
HY-P1202
CYN 154806Somatostatin SST2 Receptor Antagonist -
HY-111615
J-2156SST4 Receptor Agonist -
HY-105172
TT-232SSTR1/SSTR4 Agonist -
HY-108498
L-817818Somatostatin Receptor Agonist -
HY-P2090A
Angiopeptin TFAsst2/sst5 Receptor Partial Agonist -
HY-P1201
CyclosomatostatinSomatostatin Receptor Antagonist
Publications Citing Use of MedChemExpress (MCE) AGI-41998
More
Biological Activity
Description
In Vitro
AGI-41998 (4 days) inhibits HCT-116 MTAP-null and HCT-116 MTAPWT cell lines with GI50s of 66 nM and 1.65 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Parmacokinetics
| Species | Dose | Route | CL | Vss | MRT | Cmax | AUC0-24 |
|---|---|---|---|---|---|---|---|
| Mice[1] | 10 mg/kg | p.o. | 0.354 L/h | 12.3 L/kg | 34.7 h | 4.90 μg/mL | 77.9 μg·h/mL |
In Vivo
AGI-41998 (30-60 mg/kg, p.o., once daily for 13 days) significantly inhibits tumor growth in KP4 xenograft mice models[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Human pancreatic ductal carcinoma (KP4) xenograft tumor model established in 5- to 6-week-old severe acquired immunodeficiency female Nu/Nu mice[1]
-
Dosage:30 and 60 mg/kg
-
Administration:Oral administration (p.o.), once daily for 13 days
-
Result:Significantly inhibited the growth of KP4 tumors at 60 mg/kg dose.
Decreased the SAM level in tumors by approximately 80%.
No significant weight loss.
Chemical Information
-
CAS No. 2377492-26-5
-
Appearance Solid
-
Molecular Weight 505.29
-
Formula C22H16BrF3N4O2
-
Color Light yellow to yellow
-
SMILES
O=C1C(C2=CC=C(Br)C=C2)=C3N=C(NCC(F)(F)F)N=CC3=CN1C4=CC=C(OC)C=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
J Med Chem
Design and Discovery of Pyridazinone-Based MAT2A Inhibitors Targeting MTAP-Deficient Cancers. [Abstract]2026 May 14;69(9):10104-10121. PMID: 42024642
Solvent & Solubility
In Vitro:
DMSO : 83.33 mg/mL (164.92 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.12 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9791 mL | 9.8953 mL | 19.7906 mL | 49.4765 mL |
| 5 mM | 0.3958 mL | 1.9791 mL | 3.9581 mL | 9.8953 mL | |
| 10 mM | 0.1979 mL | 0.9895 mL | 1.9791 mL | 4.9477 mL | |
| 15 mM | 0.1319 mL | 0.6597 mL | 1.3194 mL | 3.2984 mL | |
| 20 mM | 0.0990 mL | 0.4948 mL | 0.9895 mL | 2.4738 mL | |
| 25 mM | 0.0792 mL | 0.3958 mL | 0.7916 mL | 1.9791 mL | |
| 30 mM | 0.0660 mL | 0.3298 mL | 0.6597 mL | 1.6492 mL | |
| 40 mM | 0.0495 mL | 0.2474 mL | 0.4948 mL | 1.2369 mL | |
| 50 mM | 0.0396 mL | 0.1979 mL | 0.3958 mL | 0.9895 mL | |
| 60 mM | 0.0330 mL | 0.1649 mL | 0.3298 mL | 0.8246 mL | |
| 80 mM | 0.0247 mL | 0.1237 mL | 0.2474 mL | 0.6185 mL | |
| 100 mM | 0.0198 mL | 0.0990 mL | 0.1979 mL | 0.4948 mL |
AGI-41998 Related Classifications
HY-145778 Related Classifications
Powered by Bioz